Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Silmitasertib in Healthy Subjects
NCT05817708Phase 1Completed
- Sponsor
- Senhwa Biosciences, Inc.
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of silmitasertib in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Senhwa Biosciences, Inc. Primary endpoint: Treatment-emergent Adverse Events. Started Nov 2022; status: completed.
02
Drugs
silmitasertib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05817708.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05817708.